The following information has been compiled from publicly available sources,
StratCom does not assume any responsibility for the accuracy or the authenticity
of the information and StratCom cannot be held liable for errors.
Binax, Inc. received FDA clearance to market for the rapid NOW Influenza A & B test that can identify flu A and flu B and differentiate between the two.
Calypte Biomedical Corporation has acquired an exclusive license to Ani Biotech's new patent pending rapid diagnostic test platform and sample applicator technology. Calypte will use the technology to develop rapid diagnostic tests for HIV, HPV, Hepatitis B, Hepatitis C, Syphilis, Gonorrhea, and Chlamydia in urine or oral fluid. Calypte has also been granted a non-exclusive license to develop the same STD diagnostic tests in blood, serum, plasma, or urogenital swabs. Calypte will market these new assays in the US, Europe, japan and developing countries.
Chronix Biomedical is developing Chronix Goettingen Living Test for BSE-Susceptibility, a test for Creutzfeldt-Jakob Disease in blood units. Chronix's technology is based on circulating nucleic acids. Chronix Biomedical will initiate discussions with corporate partners to assist in bringing this new CJD test to market.
Dade Behring, the University of Frankfurt and Innovectis signed an exclusive license agreement which provides Dade Behring with worldwide rights for the inventions of Professor Zeiher's group at the University of Frankfurt that relate to placental growth factor for cardiovascular diseases, soluble CD40 ligand for the prognosis of the course of disease in acute coronary syndrome and additional markers for cardiovascular diseases.
Nymox Pharmaceutical Corporation is developing a method and device for using saliva to determine cholesterol levels.
Sigma Medical, a division of Sigma Global Corporation has introduced a comprehensive health maintenance program for diabetes at only $0.99 a day. The Sigma Diabetes Maintenance program includes a full line of glucose meters, test strips, lancets and oral diabetic medications, as well as patient educational materials.
Trinity Biotech plc received FDA clearance for the use of its Uni-Gold Recombigen HIV Test with finger stick whole blood samples. The rapid test is now approved for the detection of antibodies to HIV in human serum, plasma, venous and finger stick whole blood.
![[Page Banner Image]](images/hprods.gif){kind=small}
![[HRule Image]](images/div.jpg){kind=small}
